Amgen (AMGN) is facing an antitrust lawsuit in the US filed by Sandoz, accusing Amgen of "extending and entrenching" the leading market position of its Enbrel medicine, also known as etanercept.
Sandoz said Monday that Amgen "blocked competition" from Enbrel biosimilars, including Erelzi from Sandoz, by illegally acquiring and using certain patent rights to entrench its market position.
Enbrel is approved in the US for patients with disabling inflammatory diseases and Sandoz said it received US FDA approval for Erelzi in 2016.
Apart from damages, Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block Enbrel's biosimilar competition and allow it to launch Erelzi, according to the statement.
Amgen did not immediately respond to a request for comment from MT Newswires.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.